BeOne Medicines AG (BEIGF)

Market Cap	43.72B +24.6%
Revenue (ttm)	6.13B +34.3%
Net Income	655.71M
EPS	5.59
Shares Out	n/a
PE Ratio	66.67
Forward PE	46.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	21.95
Previous Close	21.95
Day's Range	21.95 - 21.95
52-Week Range	21.95 - 24.92
Beta	0.61
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 10, 2026

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 12,000
• Stock Exchange: OTCMKTS
• Ticker Symbol: BEIGF

Financial Performance

Data Sources: S&P Global Market Intelligence and Alpha Vantage

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Alpha Vantage.

Last checked:

Oct 21, 2026

Data Sources Report a data error